VIDEO: Should ACAM2000 be a first-line monkeypox vaccine? Two experts debate
Click Here to Manage Email Alerts
WASHINGTON — Should ACAM2000 be a first-line vaccine in the current monkeypox outbreak? That was the topic of a pro/con debate during a “clinical controversies” session at IDWeek.
In this video filmed before their debate, Diane Havlir, MD, professor of medicine at the University of California, San Francisco, and chief of the division of HIV and infectious diseases at San Francisco General Hospital, argues that ACAM2000 should not be a first-line vaccine because it is more toxic and more complicated to administer than the Jynneos vaccine, which is the main vaccine being used during the monkeypox outbreak.
David P. Holland, MD, MHS, FIDSA, an associate professor of medicine in the division of infectious diseases at Emory University and chief clinical officer at the Fulton County Board of Health in Atlanta, argues that patients should be allowed to choose between the two vaccines.
Reference:
CDC. Interim clinical considerations for use of Jynneos and ACAM2000 vaccines during the 2022 U.S. monkeypox outbreak. https://www.cdc.gov/poxvirus/monkeypox/health-departments/vaccine-considerations.html. Updated Oct. 19, 2022. Accessed Oct. 21, 2022.
Havlir D, Holland DP. ACAM2000 should be a first-line vaccine in the current monkeypox outbreak: Pro/Con. Presented at: IDWeek; Oct. 19-23, 2022; Washington (hybrid meeting).
Collapse
Healio Interview.
Read more about
Click Here to Manage Email Alerts